208772-23-0 Usage
General Description
4-Benzoxazolecarboxylic acid is a chemical compound that belongs to the class of benzoxazole derivatives and contains a carboxylic acid functional group. It is a white to off-white solid at room temperature and is sparingly soluble in water. 4-Benzoxazolecarboxylic acid is commonly used as a building block in the synthesis of various pharmaceuticals, agrochemicals, and other organic compounds. It is also known for its potential biological activities, including antimicrobial, antiviral, and anti-inflammatory properties. Additionally, 4-Benzoxazolecarboxylic acid has been studied for its potential use in the development of new materials and as a fluorescent dye in biological and chemical research applications.
Check Digit Verification of cas no
The CAS Registry Mumber 208772-23-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,8,7,7 and 2 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 208772-23:
(8*2)+(7*0)+(6*8)+(5*7)+(4*7)+(3*2)+(2*2)+(1*3)=140
140 % 10 = 0
So 208772-23-0 is a valid CAS Registry Number.
208772-23-0Relevant articles and documents
Compound serving as IRAK inhibitor
-
Paragraph 0093-0096, (2020/09/01)
The present invention relates to a compound suitable for the treatment of cancer and inflammatory diseases associated with interleukin-1 receptor associated kinase (IRAK), particularly relates to a compound serving as an IRAK4 inhibitor and a preparation
2-ALKYLBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS
-
Page/Page column 14-15, (2008/12/08)
Compounds of formulae I and II: are disclosed as 5-HT3 inhibitors. Those compounds are useful in treating CINV, IBS-D and other diseases and conditions.
Benzamide derivatives having a vasopressin antagonistic activity
-
, (2008/06/13)
This invention relates to new benzamide derivatives having a vasopressin antagonistic activity, etc. and represented by general formula (I): wherein R1is aryl optionally substituted with lower alkoxy, etc., R2is lower alkyl, etc., R3is hydrogen, etc., A is NH, etc., E is etc., X is —CH═CH—, —CH═N—, or S, and Y is a condensed heterocyclic group, etc., and pharmaceutically acceptable salts thereof, to processes for preparation thereof and to a pharmaceutical composition comprising the same.
